A combination of saturation and site-directed mutagenesis was utilized to disrupt the alpha 2 domain disulfide bridge of HLA-A*0201. Mutation of cysteine 101 to a serine (C101S) or of cysteine 164 to alanine (C164A) decreased the rate of maturation of the heavy chain, the total amount of mature heavy chain within the cell, and the level of surface expression. Cells expressing these genes and loaded with a synthetic peptide derived from the influenza A matrix protein (58-66) were recognized poorly by HLA-A*0201-restricted, peptide-specific CTLs. Cells expressing mutant HLA-A*0201 loaded with a synthetic peptide derived from the HIV-1 pol protein (476-484) were not recognized by pol IV-9-specific CTLs. Mutant C164A cells infected with influenza virus were partially recognized by influenza matrix peptide-specific CTLs, while C101S cells were not lysed. Surprisingly, endogenous peptide loading of cells expressing mutant HLA-A*0201 using a minigene coding for either the influenza A matrix peptide 58-66, or

The underlying basis for HLA class I gene-associated risk in type 1 diabetes is not known. In an attempt to elucidate this, in the current study we manufactured an HLA class I negative human cell line to express the type 1 diabetes-risk allele HLA-A24 and also PPI, a major β-cell-specific autoantigen targeted in the disease. We used sensitive mass spectrometry to examine the HLA-associated peptides that these cells display. A 9-mer sequence from the signal peptide region of PPI, LWMRLLPLL, was identified as naturally processed and presented by HLA-A24 under these conditions. This PPI epitope was confirmed as being recognized by CD8 T cells in the peripheral blood using HLA-A24 tetramers loaded with LWMRLLPLL. Moreover, circulating CD8 T cells recognizing this peptide were significantly more frequent in patients with type 1 diabetes than in control subjects matched for HLA-A*24. It is important that disease relevance was substantiated by the demonstration that a CD8 T-cell clone specific for ...

TY - JOUR. T1 - Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. AU - Kono, Koji. AU - Rongcun, Yang. AU - Charo, Jehad. AU - Ichihara, Fumiko. AU - Celis, Esteban. AU - Sette, Alessandro. AU - Appella, Ettore. AU - Sekikawa, Takayoshi. AU - Matsumoto, Yoshiro. AU - Kiessung, Rolf. PY - 1998. Y1 - 1998. N2 - We have derived HLA-A2.1-restricted, gastric cancer-specific cytotoxic T lymphocyte (CTL) lines by repetitive in vitro stimulation of tumor- associated lymphocytes (TAL) with autologous tumor cells. The HER2/neu specificity of these gastric cancer-specific CTLs was demonstrated using HER2/neu-transfected cell lines and HER2/neu-expressing tumors, and with a set of HER2/neu-derived peptide epitopes. Gastric cancer-specific CTLs specifically lysed autologous and allogeneic HLA-A2.1 +, HER2/neu+ gastric cancer cells, HER2/neu-transfected CIR/A2 cell lines (HLA-A2.1+, HER2+) and HLA-A2.1-transfected SW626 tumor cell lines ...

Deborah Kronenberg, Robin R. Knight, Megan Estorninho, Richard J. Ellis, Michel G. Kester, Arnoud de Ru, Martin Eichmann, Guo C. Huang, Jake Powrie, Colin M. Dayan, Ania Skowera, Peter A. van Veelen, Mark Peakman ...

We demonstrated that each of the three (β-tublin5-154, β-tublin5-309, and CGI37-72) HLA-A31-restricted CTL-epitope peptides had the ability to induce HLA-A3-, -A11-, and -A33-restricted and tumor-reactive CTLs, from the PBMCs of epithelial cancer patients. These four alleles (HLA-A0301, -A1101, -A3101, and -A3301) along with HLA-A6801 allele share the similar binding motifs, and, thus, are classified under the HLA-A3 supertype, which is dominant in the human population (11) . Namely, the phenotypic frequency of the HLA-A3 supertype except for HLA-A6801 allele is ∼30%, 35%, 44%, 52%, and 35% among Caucasians, North American African-Americans, Japanese, Chinese, and Hispanics, respectively (11) . Although HLA-A3303 is not included in the A3 supertype classically, it was reported that HLA-A3303 binding peptides shared the same anchor residues for HLA-A3101 binding peptides (19 , 20) . We used HLA-A3303+ PBMCs in this study, instead of HLA-A3301 for the experiments, because it is a predominant ...

Hemi-exon shuffling and site-directed mutagenesis have been used to determine which amino acid differences between HLA-A2.1 and HLA-A2.2 alter the CTL-defined epitopes on these two molecules. Two genes were constructed that encode novel molecules in which the effect of amino acid differences at residues 9, 43, and 95, or at residue 156 could be separately evaluated. Using both human and murine CTL that were specific for either HLA-A2.1 or HLA-A2.2, four types of epitopes were identified: 1) epitopes that were insensitive to substitutions at either residues 9, 43, and 95, or residue 156 but were lost when all four positions were changed; 2) epitopes that were dependent on the residues 9, 43, 95, but not residue 156; 3) epitopes that were dependent on residue 156, but not amino acid residues 9, 43, and 95; and 4) epitopes that were dependent on residues 9, 43, and 95, as well as amino acid residue 156. Overall, there was a roughly equal distribution of clones recognizing each of these types of ...

Differential expression of WT1 in most leukemias (17 , 18 , 19) and several solid tumors (20 , 21 , 22 , 23) has stimulated interest in WT1 as a potential target for immunotherapy. Initially, Ohminami et al. (9) isolated a CD8+ T-cell clone, termed TAK-1, which recognized the HLA-A2402+-binding WT1 peptide 235-243CMTWNQMNL. TAK-1 exhibited HLA-A2402-restricted cytotoxic activity against WT1+ leukemias and lymphomas, lysed WT1+ HLA-A2402+ lung cancer cell lines, and inhibited the growth of HLA-A2402+ WT1+ lung cancer cell-line xenografts in nude mice (24) . Oka et al. (10) subsequently sensitized T cells from one HLA-A0201+ donor with T2 cells loaded with WT1 nonapeptides that contained major anchoring motifs for HLA-A0201, including RMF and SLG. T cells, sensitized with RMF, lysed HLA-A0201+ EBV-BLCLs loaded with peptide and WT1+ HLA-A0201+ leukemic cell lines. In a different approach, Gao et al. (11) used Drosophila cells transduced to express human HLA-A0201 and/or T2 cells loaded with ...

HLA-A2 antibody [BB7.2] (major histocompatibility complex, class I, A) for FACS, IHC-Fr, IP. Anti-HLA-A2 mAb (GTX75803) is tested in Human samples. 100% Ab-Assurance.

HLA-A antibody (major histocompatibility complex, class I, A) for ICC/IF, IHC-P, WB. Anti-HLA-A pAb (GTX54099) is tested in Human, Mouse samples. 100% Ab-Assurance.

Maus Monoklonal HLA-A Antikörper für FACS, IP, IHC. Publiziert in 9 Pubmed Referenzen. Jetzt diesen anti-HLA-A Antikörper bestellen. | Produkt ABIN2662341

Rabbit polyclonal antibody raised against a full-length human HLA-A protein. HLA-A (NP_002107.3, 1 a.a. ~ 365 a.a) full-length human protein. (H00003105-D01) - Products - Abnova

4F7P: Cross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive Individuals.

As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.

Encompassing all HLA molecules, this high-throughput computational method lends itself to epitope searches that are not only genome- and pathogen-wide, but also HLA-wide. Thus, it offers a truly global analysis of immune responses supporting rational development of vaccines and immunotherapy. It als …

By Day 4 of her familys 10-day Outer Banks beach vacation, Niki Campbell hopes to finally be in full vacation mode. About time, considering she has been working overtime for more than a month to

TY - JOUR. T1 - A novel HLA-A*03 allele, HLA-A*03:71. AU - Yu, M.. AU - Hall, J. E.. AU - Hartman, K.. AU - Czech, J.. AU - Jennings, L.. PY - 2010/10/1. Y1 - 2010/10/1. N2 - A novel HLA-A*03 allele, HLA-A*03:71, was identified by PCR sequence-based typing.. AB - A novel HLA-A*03 allele, HLA-A*03:71, was identified by PCR sequence-based typing.. KW - 03:71. KW - HLA-A. KW - PCR-SBT. KW - new allele. UR - http://www.scopus.com/inward/record.url?scp=77956308264&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=77956308264&partnerID=8YFLogxK. U2 - 10.1111/j.1399-0039.2010.01532.x. DO - 10.1111/j.1399-0039.2010.01532.x. M3 - Article. C2 - 20630036. AN - SCOPUS:77956308264. VL - 76. JO - HLA. JF - HLA. SN - 2059-2302. IS - 4. ER - ...

TY - JOUR. T1 - Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. AU - Vonderheide, Robert H.. AU - Anderson, Karen S.. AU - Hahn, William C.. AU - Butler, Mark O.. AU - Schultze, Joachim L.. AU - Nadler, Lee M.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Purpose: We have reported previously that the telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT), is a widely expressed tumor-associated antigen recognized by CTLs. A nine-amino acid peptide derived from hTERT binds strongly to HLA-A2 antigen and elicits CTL responses against a broad panel of hTERT+ tumors (but not hTERT+ hematopoietic progenitor cells). The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen. Experimental Design: Using a method of epitope deduction, HLA-A3-restricted peptide epitopes were screened ...

Aims/hypothesis The rate of progression from islet autoimmunity to clinical type 1 diabetes depends on the rate of beta cell destruction. The HLA-A*24 gene is associated with early diabetes onset, but previous studies have shown attenuated humoral responses to islet antigens in individuals with both recent and long-standing type 1 diabetes carrying HLA-A*24. We aimed to establish whether HLA-A*24 is also associated with attenuated humoral responses in individuals at high risk of type 1 diabetes. Methods We established HLA-A*24, DQ and rs9258750 (an HLA-A*24 tagged single-nucleotide polymorphism) genotype, as well as GAD, zinc transporter 8 (ZnT8), insulin, islet antigen-2 (IA-2), and IA-2β autoantibody status in 373 islet cell antibody-positive first-degree relatives participating in the European Nicotinamide Diabetes Intervention Trial. Results Univariate regression analyses showed that humoral responses to GAD, ZnT8 and insulin were less common in relatives carrying HLA-A*24. The prevalence ...

HLA-A30 (A30) is a human leukocyte antigen serotype within HLA-A serotype group. The serotype is determined by the antibody recognition of α30 subset of HLA-A α-chains. For A30, the alpha A chain are encoded by the HLA-A*30 allele group and the β-chain are encoded by B2M locus. A30 and A*30 are almost synonymous in meaning. A30 is a split antigen of the broad antigen serotype A19. A30 is a sister serotype of A29, A31, A32, A33, and A74. A*3002 alters Type 1 diabetes risk Arce-Gomez B, Jones EA, Barnstable CJ, Solomon E, Bodmer WF (February 1978). The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens. 11 (2): 96-112. doi:10.1111/j.1399-0039.1978.tb01233.x. PMID 77067. Allele Query Form IMGT/HLA - European Bioinformatics Institute Middleton D, Menchaca L, Rood H, Komerofsky R (2003). New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens. 61 (5): 403-7. doi:10.1034/j.1399-0039.2003.00062.x. PMID ...

HLA-A2 is present at high frequency in most populations, as identified by serological and biochemical means. The value of these methods is limited by their failure to discriminate between the products of the 14 known allelic HLA-A*02 variants. The great majority of genetic polymorphism which defines the allelic variants is found in exons 2 and 3 of the A*02 genes. These exons encode the alpha-1 and alpha-2 domains of the HLA Class I molecules, and variation within the genes may influence the peptide binding specificity of the gene products of each allele. Failure to accurately assign the allelic types has implications in transplantation, in interpretation of cellular assays and in the understanding of HLA disease associations. We have developed a method for determining the 14 known alleles of HLA-A*02 by use of ARMS-PCR to determine the degree of variation of HLA-A*02 alleles in 3 different population groups. Considerable variation was found in the relative frequencies of particular A*02 alleles between

It was shown that oncogenes, such as ras, myc, and HER2, can induce the downregulation of MHC class I surface expression, resulting in an escape from immunosurveillance (12, 24-27). However, there is limited information about epigenetic and oncogenic factors for downregulation of HLA-class I. To our knowledge, only one previous study (24) reported that joint action of DNA methylation and MAPK inhibition could exert a regulatory effect on HLA-A expression in colon cancer cells. In the current study, we expanded this anecdotal observation to a more general phenomenon, showing that the MAPK pathway could regulate HLA-A expression in gastric and esophageal cancer. In addition, we showed that HLA-A expression is predominantly regulated by the MAPK pathway but is influenced, in part, by the Akt pathway, as shown by the HER1 and HER3 experiments (Fig. 8), and the lapatinib treatment (Figs. 1, 4).. Although p-Akt and p-Erk were both almost completely inhibited by lapatinib in HER2-overexpressing cells ...

Brilliant Violet 510™ anti-human HLA-A,B,C Antibody - MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells.

MHC/peptide complexes provide a specific and unique target for immune-based therapeutic approaches. Hence an antibody that mimics the specificity of cytotoxic T lymphocytes and recognises MHC/peptide complexes on the surface of tumour cells, represents an attractive new targeting strategy. We have developed a T cell receptor-like antibody which targets EBV nuclear antigen 1 (EBNA-1) in the context of HLA-A201 using conventional hybridoma techniques with a high degree of specificity. In our study, we detail the generation and characterisation of this monoclonal antibody. We demonstrate that this antibody exhibits a specific binding pattern and binds with high affinity to HLA-A201/EBNA-1 complexes on the surface of EBV transformed B-lymphoblastoid cell lines, tumour cell lines and NPC biopsies. In addition, this antibody is able to detect constitutive levels of HLA-A201/EBNA-1 complexes and as such represents a novel reagent for EBV research and for targeting EBV-associated malignant cells ...

Allele 5 at the microsatellite locus D6S265 (D6S265*5), 100 kb centromeric of HLA-A, showed strong positive association with disease (OR = 4.7, Pc , 10-6). Haplotype analysis demonstrated that the D6S265*5 association was not caused by LD to the gene encoding HLA-A*02, which has previously been described also to be associated with JIA. Rather our data suggest that a gene in LD with D6S265*5, but distinct from HLA-A*02, is involved in predisposition to JIA. ...

HLA-A3 Mouse anti-Human, FITC, Clone: GAP.A3, eBioscience™ 25 tests; FITC HLA-A3 Mouse anti-Human, FITC, Clone: GAP.A3, eBioscience™ Primary Antibodies Hj...

HLA-A2 Mouse anti-Human, PerCP-eFluor 710, Clone: BB7.2, eBioscience™ 25 tests; PerCP-eFluor 710 HLA-A2 Mouse anti-Human, PerCP-eFluor 710, Clone: BB7.2,...

p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.,/p> ,p>It should be noted that while, in theory, two different sequences could have the same checksum value, the likelihood that this would happen is extremely low.,/p> ,p>However UniProtKB may contain entries with identical sequences in case of multiple genes (paralogs).,/p> ,p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64) using the generator polynomial: x,sup>64,/sup> + x,sup>4,/sup> + x,sup>3,/sup> + x + 1. The algorithm is described in the ISO 3309 standard. ,/p> ,p class=publication>Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.,br /> ,strong>Cyclic redundancy and other checksums,/strong>,br /> ,a href=http://www.nrbook.com/b/bookcpdf.php>Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993),/a>),/p> Checksum:i ...

NetMHC version 4.0 # Input is in FSA format # Peptide length 8,9 # Affinity Threshold for Strong binding peptides 50.000 # Affinity Threshold for Weak binding peptides 500.000 # Rank Threshold for Strong binding peptides 0.500 # Rank Threshold for Weak binding peptides 2.000 ----------------------------------------------------------------------------------- pos HLA peptide Core Offset I_pos I_len D_pos D_len iCore Identity 1-log50k(aff) Affinity(nM) %Rank BindLevel ----------------------------------------------------------------------------------- 0 HLA-A0301 TPQDLNTM -TPQDLNTM 0 0 1 0 0 TPQDLNTM Gag_180_209 0.014 43017.00 95.00 1 HLA-A0301 PQDLNTML PQDLNTML- 0 8 1 0 0 PQDLNTML Gag_180_209 0.021 39881.02 80.00 2 HLA-A0301 QDLNTMLN -QDLNTMLN 0 0 1 0 0 QDLNTMLN Gag_180_209 0.018 41073.47 85.00 3 HLA-A0301 DLNTMLNT DLN-TMLNT 0 3 1 0 0 DLNTMLNT Gag_180_209 0.019 40552.86 85.00 4 HLA-A0301 LNTMLNTV -LNTMLNTV 0 0 1 0 0 LNTMLNTV Gag_180_209 0.035 34098.43 55.00 5 HLA-A0301 NTMLNTVG NTMLNTVG- 0 8 1 0 0 ...

Mouse monoclonal antibody raised against a full-length recombinant HLA-A. HLA-A (AAH03069, 24 a.a. ~ 365 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. (H00003105-M01) - Products - Abnova

Roedewald, H. R.; Koszinowski, Ulrich H.; Eichmann, K. und Melchers, I. (1989): Predominant utilization of V beta 8+ T cell receptor genes in the H-2Ld- restricted cytotoxic T cell response against the immediate-early protein pp89 of the murine cytomegalovirus. In: The Journal of Immunology, Vol. 143: S. 4238-4243 [PDF, 644kB] ...

HLA-A*02:01 PRAME142-151 Tetramer-SLYSFPEPEA-APC（Human Class I） from MBL.MHC tetramers can be used for direct detection of antigen specific T cells.

Human immune response molecule complex. Molecular model showing a human T-cell receptor (blue, brown) and an HLA-A leukocyte (white blood cell, yellow) antigen bound to a TAX peptide (magenta) from a virus and beta-2 microglobulin (green). The HLA-A molecule presents the viral peptide to the T-cell, a component of the immune system, activating it. The T-cell then destroys the cells infected by the virus. - Stock Image C035/8619

We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...

https://doi.org/10.18632/oncotarget.16900 Laurie Rangan, Jeanne Galaine, Romain Boidot, Mohamad Hamieh, Magalie Dosset, Julie Francoual, Laurent Beziaud, Jean-René Pallandre, Elodie Lauret Marie...

After nearly 10 years of researches and testing I managed to develop a cure for acne, without side effects. Thanks to researches and development my acne treatment are working harder, stronger and faster than ever before. First of all you should know that this treatment is very serious and effective and easy to use. My treatment is applied on the affected skin, so no liver and kidneys damage or depression. This treatment follows fighting bacterial infection, reducing the inflammation and reducing the oil production.My treatment is a gel, have skin color and you can keep it on the skin all day long. I recommend you to keep it on the skin when you do your daily activities, to protect your skin against dust, pollution, cigarette smoke, sunlight (UV). Our skin come in contact daily with 150 chemicals, some are very irritating and toxic for skin (especially facial skin). A good acne treatment works from first day. ...

TY - JOUR. T1 - Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. AU - Nukaya, I.. AU - Yasumoto, M.. AU - Iwasaki, T.. AU - Ideno, M.. AU - Sette, A.. AU - Celis, E.. AU - Takesako, K.. AU - Kato, I.. PY - 1999/1/5. Y1 - 1999/1/5. N2 - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing ...

Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone. Vascular endothelial growth factor receptor type 1 (VEGFR1) is expressed on the tumor vessels and a candidate of tumor vessel-specific peptide vaccination strategy to induce T cell immune response. We conducted the study to confirm the safety and efficacy of combined modality intervention using conventional dose of gemcitabine with peptide vaccination targeting tumor-vessel specific VEGFR1 in case of advanced/inoperable or therapy-resistant pancreatic cancer patients.. Gemcitabine 1,000 mg/m^2 (body surface area) will be administered on day 1, day 8, day 15, day 29, day 36, and day 43, respectively.. VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A02-770; TLFWLLLTL) emulsified with Montanide ISA51 will be subcutaneously injected twice weekly for 8 weeks (total 16 doses). ...

The colorectal cell line HCA-7 expresses surface human leucocyte antigen-A*0201 (HLA-A*0201), but lacks expression of HLA-A*0101 whilst the normal B-cell line (EVA-1224), derived from the same individual, expresses both surface HLA-A1 and HLA-A2. Amplification refractory mutation system-polymerase chain reaction analysis, using sequence-specific primers, suggested that HCA-7 has a mutation in a 7 base pair (bp) cytosine repeat sequence located at the beginning of Exon 4 (bp 621-627). Cloning and sequencing revealed HCA-7 to have eight cytosine residues in this repeat sequence. In contrast, EVA-1224 contained only 7 cytosines. Analysis of the mRNA for HLA-A*010 using reverse trancriptase-polymerase chain reaction (RT-PCR), with an allele-specific 5 primer in exon 2 (bp 253-271) and a series of 3 primers in exons 3, 4 and 7 and in the 3untranslated region, revealed that HCA-7 contained a shortened message terminating in the region of the exon 3/4 boundary. The insertion of an extra cytosine in this

Two different BALB/c anti-CBA (H-2k)monoclonal antibodies that bind to Kk and Dk antigens blocked Tc cell-mediated lysis of L929 (Kk, Dk) target cells, but with

HLA-A1 (A1) is a human leukocyte antigen serotype within HLA-A A serotype group. The serotype is determined by the antibody recognition of α1 subset of HLA-A α-chains. For A1, the alpha A chain are encoded by the HLA-A*01 allele group and the β-chain are encoded by B2M locus. This group currently is dominated by A*0101. A1 and A*01 are almost synonymous in meaning. A1 is more common in Europe than elsewhere, it is part of a long haplotype that appears to have been frequent in the ancient peoples of Northwestern Europe. A1 is a frequent component of the AH8.1 haplotype. A1 serotype positivity is roughly linked to a large number of inflammatory diseases and conditions believed to have immune system involvement. Because of its linkage within the AH8.1 haplotype many studies showed association with A1 or A1,B8 only later to show the association drift toward the class II region gene alleles, DR3 and DQ2.5. While it is not clear what role A1 has in infectious disease, some linkage with ...

In disease states which involve tissue destruction and immune-mediated cell lysis, the identification and characterization of autoreactive T lymphocyte responses, and the nature of the peptide and the MHC encoded restricting element, is an important step in defining the role of these cells in disease pathogenesis. Previous work has focused on the characterization of CD4+ T cell lines and CD4+ T cell clones specific for PDC-E2 (17, 18). However, little work has been performed to define the CD8+ CTL response in PBC. Immunohistochemical studies reveal that the portal infiltrates in PBC are predominantly CD3+ T cells containing both CD8+ and CD4+ subsets bearing the 2β-TCR. The CD4/CD8 ratio ranges from 2-2.5:1 (19, 20). CD8+ T cells are most abundant during early stages of disease and as the disease progresses, a higher proportion of CD4+ T cells are observed (21, 22). In this paper, we identified PD5 as an HLA-A2-restricted epitope on PDC-E2, the major target protein of autoreactive Ab in PBC. ...

Tumor-associated antigens (TAA) are monomorphic self-antigens that are proposed as targets for immunotherapeutic approaches to treat malignancies. We investigated whether T cells with sufficient avidity to recognize naturally overexpressed self-antigens in the context of self-HLA can be found in the T-cell repertoire of healthy donors. Minor histocompatibility antigen (MiHA)-specific T cells were used as model, as the influence of thymic selection on the T-cell repertoire directed against MiHA can be studied in both self (MiHApos donors)and non-self (MiHAneg donors) backgrounds. T-cell clones directed against the HLA*02:01-restricted MiHA HA-1H were isolated from HA-1Hneg/HLA-A*02:01pos and HA-1Hpos/HLA-A*02:01pos donors. Of the 16 unique HA-1H-specific T-cell clones, 5 T-cell clones derived from HA-1Hneg/HLA-A*02:01pos donors and 1 T-cell clone derived from an HA-1Hpos/HLA-A*02:01pos donor showed reactivity against HA-1Hpos target cells. Additionally, in total 663 T-cell clones (containing at ...

A specific HLA-A Surface Antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*01 Allele Family ...

Freshly Isolated Influenza Peptide-specific CD8+ T Cells from Donors Without Active Influenza Infection Display Effector Function Within 6 h of Antigen Contact. Unrestimulated CD8+ T cells, freshly isolated from the peripheral blood of donors in the memory state with respect to influenza virus, secreted IFN-γ within 6 h of contact with HLA class I-restricted influenza peptide epitopes. Fig. 1,A quantitates CD8+ T cells that display effector function within 6 h of exposure to antigen; T cells specific for the HLA-A2.01- restricted influenza matrix epitope, M1 58-66, were detected in PBMCs freshly isolated from donor SM with HLA-A2.01. The number of IFN-γ SFCs did not increase when PBMCs were incubated in the ex vivo ELISPOT assay for periods of time progressively longer than 6 h, up to 40 h (data not shown). Negative controls in the ELISPOT assay were wells with PBMCs but no peptide or irrelevant peptides from infectious agents with which the donor was not infected. These never elicited a ...

p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.,/p> ,p>It should be noted that while, in theory, two different sequences could have the same checksum value, the likelihood that this would happen is extremely low.,/p> ,p>However UniProtKB may contain entries with identical sequences in case of multiple genes (paralogs).,/p> ,p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64) using the generator polynomial: x,sup>64,/sup> + x,sup>4,/sup> + x,sup>3,/sup> + x + 1. The algorithm is described in the ISO 3309 standard. ,/p> ,p class=publication>Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.,br /> ,strong>Cyclic redundancy and other checksums,/strong>,br /> ,a href=http://www.nrbook.com/b/bookcpdf.php>Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993),/a>),/p> Checksum:i ...

HLA-A*02:01 EBV LMP2 I6M Tetramer-TVCGGMMFL-PE（Human Class I） from MBL.MHC tetramers can be used for direct detection of antigen specific T cells.

4844 Tie-2 stabilises pericyte/endothelial interactions during angiogenesis and is over expressed on tumor endothelium. A vaccine that targets endothelium over-expressing Tie-2 may result in vessel damage and stimulate an inflammatory cascade resulting in disease regression. To validate the use of Tie-2 as a target, human Tie-2 was used as a xenogenic vaccine in mice. Preliminary studies suggest that immunisation of balb/c mice by gene gun with DNA from the extracellular region of Tie-2 resulted in cessation of tumor growth. To determine if we could design a syngeneic vaccine that would work in both mice and humans a conserved region of Tie- 2 was cloned. HLA-A*0201 transgenic mice were immunised with this construct to determine if a repertoire of HLA-A*0201 T cells exist that recognise Tie-2. Within the Tie-2 region an HLA-A*0201 epitope was identified that is identical between mice and humans. Anchor modification of this epitope, increased binding to MHC. Immunisation of HLA-A*0201 mice with ...

EBV peptide GLCTLVAML (HLA-A*0201) for stimulation of T-cells. Single peptide (GLCTLVAML) for stimulation of human EBV BMLF-1(280-288) CD8+ T-cells. …

Stabilization of cell surface MHC by BA46-derived peptides. BA46-derived peptides were loaded at various concentrations (1-100 μM) on TAP2-deficient RMA-S-HHD cells as described, and indirect FACS analysis was performed by incubating 5 × 105 loaded cells with anti-HLA-A2.1 MAb BB7.2 for 30 minutes at 4ºC. After the cells were washed with PBS-0.5% BSA plus 0.1% sodium azide, the secondary Ab, goat anti-mouse-FITC, was applied for 30 minutes at 4ºC. Following another wash, the amounts of bound Abs were detected by a FACScan. Mean fluorescence at 1-100 μM peptide concentrations is shown. Results are representative of three similar experiments ...

SWISS-MODEL Template Library (SMTL) entry for 1qrn.1. CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A

To evaluate immunologic response (as measured by an increase in PSA specific T-cells measured by ELISPOT in HLA-A2+ patients), and clinical response (as measured by RECIST and PSA consensus criteria ...